Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
about
Pharmacogenetics of treatment response in psoriatic arthritisGenetics of rheumatoid arthritis susceptibility, severity, and treatment response.Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Communication practices and awareness of resources for acromegaly patients among endocrinologists.Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN StudyHigh frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.Genetic and genomic markers of anti-TNF treatment response in rheumatoid arthritis.Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis.Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91-108. doi:10.1007/s12325-016-0441-3Third Annual Open Meeting of the UK Pharmacogenomics and Stratified Medicine Network Conference.Characterization of adherence and persistence profile in a real-life population of patients treated with adalimumab.Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study.Intentional and unintentional medication non-adherence in psoriasis: the role of patients' medication beliefs and habit strength.Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users.Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisPatterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims databaseGenome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisA Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
P2860
Q28081252-78A3B02E-91E2-48EF-B104-A14DA039526AQ33841329-0950FCE6-9236-4BCC-8610-E81D06F140E4Q36832755-8A42A3DE-6583-4846-B901-1E3BC5962A34Q37515368-24BEACD2-0FE3-4213-8A29-34B6A367ADD9Q37562617-3D34F291-F8B4-447B-9BAC-8EF5DD921BDAQ37604498-9F90D88D-0045-49C8-9397-DC9CBCA27F98Q38529234-8EC9DDE2-7484-4E2B-9858-73C58DAEBE3AQ38665413-FF96B730-00F2-48AB-A45C-83E00ED4849AQ38856372-3E253286-6450-493C-AE5F-23A48A6E2248Q38867559-391E99A1-2FAB-4428-A687-E89D05F948EDQ39064616-4F218D51-9C6D-4E7D-93B4-F0E34CA6BD2CQ41359106-11D1FFEB-DC0C-4A07-AD2D-653AC5D603FBQ42289113-9AEFEEC8-E0C7-4C56-A6A4-0FD911BE677DQ42359106-D3816A22-3FAC-4620-B3C6-107803ED5316Q42629113-F1D5F149-1B84-45FC-AF9C-EE876BB991E7Q47258336-C7C26D6B-EFC8-4497-9985-8F299ED0BB09Q47970691-6AF083B2-7C40-4C9E-86A9-26BA05F199C6Q49568162-2727AC95-17A1-4144-A30C-1D0D9FB878ADQ53122503-CA840DD9-3020-4574-8E43-8DEDFC6D3377Q54957060-BA551D7A-4FA6-47C6-8F8E-49F02C0733CDQ56975651-E66BF27A-9881-43D3-9AD4-22E8A5A063C1Q57074034-1971EA2F-DDDA-4A0D-BE74-A528C891D6A3Q58779486-19EB780B-B67F-4615-ACBD-9C7D3C2F3BE4Q58800375-1B6FBF45-F95B-4BCF-BFF2-27BF0A957694
P2860
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@ast
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@en
type
label
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@ast
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@en
prefLabel
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@ast
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@en
P2093
P2860
P50
P356
P1433
P1476
Impact of inadequate adherence ...... enomics Study Syndicate cohort
@en
P2093
Ann W Morgan
Anthony G Wilson
Catharine Morgan
Darren Plant
Kimme L Hyrich
Layla Thurston
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEU358
P577
2014-09-10T00:00:00Z